Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

Versiani M, Mehilane L, Gaszner P, Arnaud-Castiglioni R

Institute of Psychiatry, Federal University,
Rio de Janeiro, Brazil.
J Clin Psychiatry 1999 Jun; 60(6):400-6

ABSTRACT

BACKGROUND: The long-term efficacy and tolerability of the antidepressant reboxetine, a unique selective norepinephrine reuptake inhibitor (selective NRI), were assessed in an international study. 

METHOD: Two hundred eighty-three patients with recurrent DSM-III-R major depression who responded to 6 weeks of reboxetine treatment (> or =50% decrease in Hamilton Rating Scale for Depression [HAM-D] total score) were randomly assigned to receive reboxetine or placebo for 46 weeks in a double-blind phase. Relapse (> or =50% increase in HAM-D total score and/or a HAM-D total score > or =18) rate was the principal assessment criterion and included patients who experienced relapse or recurrence. Only patients who remained relapse-free at the end of the first 6-month treatment period were included in the relapse rate assessment at the end of the second 6-month treatment period. 

RESULTS: Reboxetine was associated with a markedly lower relapse rate than placebo (22% vs. 56%; p<.001) and a greater cumulative probability of a maintained response (p = .0001) during long-term treatment. Patients in remission (HAM-D total score < or =10) at the time of random assignment were less likely to relapse (16% reboxetine, 48% placebo; p<.001). The proportion of patients who were relapse-free and therefore remained in the study was significantly (p< or =.001) higher among those on reboxetine treatment than on placebo at the end of the first (61% vs. 40%) and second (88% vs. 59%) 6 months of treatment. Additional efficacy measures supported these findings. The incidence of adverse events with reboxetine was low and comparable with that for placebo. Discontinuation due to adverse events occurred infrequently. 

CONCLUSION: Reboxetine treatment over 1 year is more effective than placebo in the prevention of relapse in patients with recurrent depression. The low relapse rates at the end of the second 6 months of treatment further suggest that reboxetine effectively prevents recurrence of depressive symptoms following episode resolution. Reboxetine is well tolerated in long-term treatment of depression, a finding that bodes well for long-term patient compliance.

Back                          to order

                Reboxetine  research / abstracts

         1.   Reboxetine  role in antidepressant therapy
         2.   Reboxetine  efficacy and tolerability
         3.   Reboxetine  clinical pharmacologic profile
         4.   Inhibiting  the reuptake of noradrenaline and serotonin
         5.   Reboxetine  and depression in the elderly
         6.   Reboxetine  with severe major depressive disorder
         7.   Reboxetine  clinical efficacy in major depression
         8.   Reboxetine  tolerability and safety for major depression
         9.   Reboxetine  comparison with fluoxetine
        10   Reboxetine  versus fluoxetine, impact on social functioning
        11.  Reboxetine  versus fluoxetine, differential effects
        12.  Reboxetine  prevents relapse in  major depression
        13   Reboxetine  efficacy compared with imipramine
        14.  Noradrenaline reuptake inhibition
        15.  Antidepressants  noradrenergic versus serotonergic 
        16.  Reboxetine  in the treatment of bulimia
        17.  Reboxetine  hemodynamic effects in healthy males
        18.  Reboxetine  effects of antidepressant therapy
        19.  Reboxetine  place in antidepressant therapy
        20.  Reboxetine  stimulant effects in patients with narcolepsy
        21.  Reboxetine  selective noradrenaline reuptake inhibitor (NARI)